New Cancer Drug
Approved in Britain - Sutent Expensive But Effective in Fighting Tumors
Two Ways - SMART Starve Tumors and Stop Growth
July 31st 2006
|
 |
|
Sutent |
|
A new line of cancer killing drugs is being offered for sale in Britain
today. The so called “SMART” drug attacks tumors by starving them of
nutrients and inhibiting the enzyme that signals cells to multiply. The
two-front approach may be better than the single approach now offered by
the extremely successful drug Glivec.
The UK based news agency, Times Online, says that the news drug, Sutent,
is “one of the latest three Glivec-like drugs that are at various stages
of development, and which cancer specialists expect to prove useful in
treating different kinds of tumours.”
Glivec inhibits the enzyme that signals cells to multiply. Since its
introduction in 2001, Glivec has transformed the treatment of chronic
myeloid leukemia and a rare form of stomach cancer. But there is hope
for more cancers too.
The Times reported that “In trials against advanced kidney cancer that
had not responded to conventional drugs, Sutent caused tumours to shrink
in 40 per cent of patients, and in a further 28 per cent they stabilised.”
A study in the US showed that Sutent stopped the progression or shrank
the tumors in half in 14 percent of patients with advanced breast
cancer. The treatment is expensive, costing around $4,500 per month per
patient. The Times reported that the British health system (NHS) may
limit its use to a second treatment only after another drug fails.
Dan Wilson
Best Syndication
Books on Dieting
Keywords and misspellings: deit pills hoodia rimonabant
rinomabant rinonant rinomabent wieght watchers |
